BACKGROUND: Treatment options for sarcoma are limited. Histone deacetylase inhibitors increase the efficacy of topoisomerase II inhibitors by promoting access to chromatin and by down-regulating DNA repair. Thus, combined panobinostat and epirubicin therapy was evaluated to treat refractory sarcoma. PATIENTS AND METHODS: Patients with advanced solid tumors were enrolled in a 3 + 3 dose-escalation phase I trial of panobinostat given on days 1, 3, and 5 followed by 75 mg/m(2) of epirubicin on day 5 in 21-day cycles, with a dose expansion at maximum tolerated dose (MTD) in 20 sarcoma patients. Peripheral blood mononucleocyte histone acetylation was also evaluated. RESULTS: Forty patients received 20-60 mg panobinostat. Dose-limiting toxicities included thrombocytopenia, febrile neutropenia, and fatigue at 60 mg, defining a panobinostat MTD at 50 mg. Four responses were seen in 37 assessable patients, all after progression on prior topoisomerase II inhibitors. For those with sarcoma, 12 of 20 derived clinical benefit (1 partial response and 11 stable disease, median overall survival 8.3 months), including 8 of 14 previously progressed on topoisomerase II therapy. Treatment benefits correlated with increased histone acetylation and decreased neutrophil count on day 5. CONCLUSIONS: Panobinostat and epirubicin treatment is well tolerated and may reverse anthracycline resistance. Changes in histone acetylation and associated decrease in neutrophil count correlated with clinical benefit and warrant investigation as predictive biomarkers. CLINICAL TRIAL: This trial is registered at www.Clinicaltrials.gov, Identifier: NCT00878904. Published by Oxford University Press on behalf of the European Society for Medical Oncology 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Treatment options for sarcoma are limited. Histone deacetylase inhibitors increase the efficacy of topoisomerase II inhibitors by promoting access to chromatin and by down-regulating DNA repair. Thus, combined panobinostat and epirubicin therapy was evaluated to treat refractory sarcoma. PATIENTS AND METHODS: Patients with advanced solid tumors were enrolled in a 3 + 3 dose-escalation phase I trial of panobinostat given on days 1, 3, and 5 followed by 75 mg/m(2) of epirubicin on day 5 in 21-day cycles, with a dose expansion at maximum tolerated dose (MTD) in 20 sarcomapatients. Peripheral blood mononucleocyte histone acetylation was also evaluated. RESULTS: Forty patients received 20-60 mg panobinostat. Dose-limiting toxicities included thrombocytopenia, febrile neutropenia, and fatigue at 60 mg, defining a panobinostat MTD at 50 mg. Four responses were seen in 37 assessable patients, all after progression on prior topoisomerase II inhibitors. For those with sarcoma, 12 of 20 derived clinical benefit (1 partial response and 11 stable disease, median overall survival 8.3 months), including 8 of 14 previously progressed on topoisomerase II therapy. Treatment benefits correlated with increased histone acetylation and decreased neutrophil count on day 5. CONCLUSIONS:Panobinostat and epirubicin treatment is well tolerated and may reverse anthracycline resistance. Changes in histone acetylation and associated decrease in neutrophil count correlated with clinical benefit and warrant investigation as predictive biomarkers. CLINICAL TRIAL: This trial is registered at www.Clinicaltrials.gov, Identifier: NCT00878904. Published by Oxford University Press on behalf of the European Society for Medical Oncology 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger Journal: Lancet Date: 2012-05-16 Impact factor: 79.321
Authors: Andelko Hrzenjak; Farid Moinfar; Marie-Luise Kremser; Bettina Strohmeier; Edgar Petru; Kurt Zatloukal; Helmut Denk Journal: Mol Cancer Date: 2010-03-04 Impact factor: 27.401
Authors: Le Su; Arthur V Sampaio; Kevin B Jones; Marina Pacheco; Angela Goytain; Shujun Lin; Neal Poulin; Lin Yi; Fabio M Rossi; Juergen Kast; Mario R Capecchi; T Michael Underhill; Torsten O Nielsen Journal: Cancer Cell Date: 2012-03-20 Impact factor: 31.743
Authors: Andelko Hrzenjak; Farid Moinfar; Marie-Luise Kremser; Bettina Strohmeier; Philipp B Staber; Kurt Zatloukal; Helmut Denk Journal: Mol Cancer Ther Date: 2006-09 Impact factor: 6.261
Authors: Gonzalo Lopez; Juehui Liu; Wenhong Ren; Wei Wei; Suizhao Wang; Guy Lahat; Quan-Sheng Zhu; William G Bornmann; David J McConkey; Raphael E Pollock; Dina C Lev Journal: Clin Cancer Res Date: 2009-05-05 Impact factor: 12.531
Authors: Darcy Welch; Elliot Kahen; Brooke Fridley; Andrew S Brohl; Christopher L Cubitt; Damon R Reed Journal: PLoS One Date: 2019-09-24 Impact factor: 3.240
Authors: Sarah B Whittle; Katharine Offer; Ryan D Roberts; Amy LeBlanc; Cheryl London; Robbie G Majzner; Alex Y Huang; Peter Houghton; E Alejandro Sweet Cordero; Patrick J Grohar; Michael Isakoff; Michael W Bishop; Elizabeth Stewart; Emily K Slotkin; Emily Greengard; Scott C Borinstein; Fariba Navid; Richard Gorlick; Katherine A Janeway; Damon R Reed; Pooja Hingorani Journal: Pediatr Blood Cancer Date: 2021-06-16 Impact factor: 3.838